A phase i evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection

New England Journal of Medicine

Volumn 324, Issue 24, 1991, Pages 1677-1684

  Redfield, Robert R ^a   Birx, Deborah L ^a   Polonis, Victoria ^a   Burke, Donald S ^b   Tramont, Edmund ^c   Brundage, John F ^c   Davis, Charles ^d   Johnson, Steven ^d   Oster, Charles ^d   Ketter, Nzeera ^e   Wierzba, Thomas ^e   Fowler, Arnold ^f   Shafferman, Avigdor ^g   Smith, Gale ^h   Volvovitz, Franklin ^h  

^a Department of Retroviral Research ^*  (United States)

^b Division of Retrovirology   (United States)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

^e H M Jackson Found Adv Mil Med   (United States)

^f SRA Technologies Inc   (United States)

^g ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

^h MicroGeneSys Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; ENVELOPE PROTEIN; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOGENICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; VACCINATION;

EID: 0025764679     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199106133242401     Document Type: Article

References (53)

1. Melbye M, Biggar RJ, Ebbesen P, et al. Long-term seropositivity for human T-lymphotrophic virus type III in homosexual men without acquired immunodeficiency syndrome: development of immunologic and clinical abnormalities: a longitudinal study. Ann Intern Med 1986; 104:496–500.
2. Redfield RR, Burke DS. Shadow on the land: the epidemiology of HIV. Viral Immunol 1987; 1:69–81.
3. Zolla-Pazner S, Des Jarlais DC, Friedman SR, et al. Nonrandom development of immunologic abnormalities after infection with human immunodeficiency virus: implications for immunologic classification of the disease. Proc Natl Acad Sci U S A 1987; 84:5404–8.
4. Giorgi JV, Fahey JL, Smith DC, et al. Early effects of HIV on CD4 lymphocytes in vivo. J Immunol 1987; 138:3725–30.
5. Fauci A. The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science 1988; 239:617–22.
6. Birx DL, Redfield RR, Tosato G. Defective regulation of Epstein–Barr virus infection in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related disorders. N Engl J Med 1986; 314:874–9.
7. Lane HC, Depper JM, Greene WC, Whalen G, Waldmann TA, Fauci AS. Qualitative analysis of immune function in patients with the acquired immunodeficiency syndrome: evidence for a selective defect in soluble antigen recognition. N Engl J Med 1985; 313:79–84.
8. Lane HC, Masur H, Edgar LC, Whalen G, Rook AH, Fauci AS. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med 1983; 309:453–8.
9. Fahey JL, Taylor JM, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 1990; 322:166–72.
10. Leitman SF, Klein HG, Melpolder JJ, et al. Clinical implications of positive tests for antibodies to human immunodeficiency virus type 1 in asymptomatic blood donors. N Engl J Med 1989; 321:917–24.
11. Phair J, Muñoz A, Detels R, et al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. N Engl J Med 1990; 322:161–5.
12. Goedert JJ, Kessler CM, Aledort LM, et al. A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med 1989; 321:1141–8.
13. Redfield RR, Wright DC, Tramont EC. The Walter Reed staging classification for HTLV-III/LAV infection. N Engl J Med 1986; 314:131–2.
14. Robert-Guroff M, Brown M, Gallo RC. HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex. Nature 1985; 316:72–4.
15. Weiss RA, Clapham PR, Cheingsong-Popov R, et al. Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. Nature 1985; 316:69–72.
16. Lyerly HK, Reed DL, Matthews TJ, et al. Anti-gp120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC. AIDS Res Hum Retroviruses 1987; 3:409–22.
17. Weinhold KJ, Lyerly HK, Matthews TJ, et al. Cellular anti-gp120 cytolytic reactivities in HIV-1 seropositive individuals. Lancet 1988; 1:902–5.
18. Koenig S, Earl P, Powell D, et al. Group-specific, major histocompatibility class I-restricted cytotoxic responses to human immunodeficiency virus 1 (HIV-1) envelope proteins by cloned peripheral blood T cells from an HIV infected individual. Proc Natl Acad Sci U S A 1988; 85:8638–42.
19. Walker BD, Chakrabarti S, Moss M, et al. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 1987; 328:345–8.
20. Berzofsky JA, Bensussan A, Cease KB, et al. Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans. Nature 1988; 334:706–8.
21. Allain J-P, Laurian Y, Paul DA, et al. Long-term evaluation of HIV antigen and antibodies to p24 and gp41 in patients with hemophilia: potential clinical importance. N Engl J Med 1987; 317:1114–21.
22. Burke DS, Fowler AK, Redfield RR, Dilworth S, Oster CN. Isolation of HIV-1 from the blood of seropositive adults. J Acquir Immune Defic Syndr 1990; 3:1159–67.
23. Schnittman SM, Greenhouse JJ, Psallidopoulos MC, et al. Increasing viral burden in CD4+ T cells from patients with human immunodeficiency virus (HIV) infection reflects rapidly progressive immunosuppression and clinical disease. Ann Intern Med 1990; 113:438–43.
24. Åsjö B, Morfeldt-Månson L, Albert J, et al. Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet 1986; 2:660–2.
25. Cheng-Mayer C, Seto D, Tateno M, Levy A. Biologic features of HIV-1 that correlate with virulence in the host. Science 1988; 240:80–2.
26. Salk J. Prospects for the control of AIDS by immunizing seropositive individuals. Nature 1987; 327:473–6.
27. Zagury D, Léonard R, Fouchard M, et al. Immunization against AIDS in humans. Nature 1987; 326:249–50.
28. Redfield RR, Burke DS. HIV infection: the clinical picture. Sci Am 1988; 259(4):90–8.
29. Dolin R, Graham BS, Greenberg SB, et al. The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. Ann Intern Med 1991; 114:119–27.
30. Rickman WF, Waxdal MJ, Monical C, Damato JD, Burke DS. Department of Army lymphocyte immunophenotyping quality assurance program. Clin Immunol Immunopathol 1989; 52:85–95.
31. Birx DL, Rhoads JL, Wright JC, Burke DS, Redfield RR. Immunologic parameters in early-stage HIV-seropositive subjects associated with vaccine responsiveness. J Acquir Immune Defic Syndr 1991; 4:188–96.
32. Wages JM Jr, Hamdallah M, Calabro MA, et al. Clinical performance of a polymerase chain reaction testing algorithm for diagnosis of HIV-1 infection in peripheral blood mononuclear cells. J Med Virol 1991; 33:58–63.
33. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 1979; 76:4350–4.
34. Lee TH, Redfield RR, Hsieh CC, et al. Association between antibody to envelope glycoprotein gp120 and the outcome of human immunodeficiency virus infection. In: Ginsbergh H, ed. Vaccine 1988: new chemical and genetic approaches to vaccination. Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory, 1988:373–7.
35. Shafferman A, Lennox J, Grosfeld H, Sadoff G, Redfield RR, Burke DS. Patterns of antibody recognition of selected conserved amino acid sequences from the HIV envelope in sera from different stages of HIV infection. AIDS Res Human Retroviruses 1989; 5:33–9.
36. Polonis V, Shafferman A, Lee T, Smith G, Burke D, Redfield R. Relationship between antibody directed against the carboxyl-terminal region of HIV GP120 and markers of HIV specific immunoregulation. J Cell Biol 1989; 109: Suppl 13B: 258. abstract.
37. Syu WJ, Huang JH, Essex M, Lee TH. The N-terminal region of the human immunodeficiency virus envelope glycoprotein gp120 contains potential binding sites for CD4. Proc Natl Acad Sci U S A 1990; 87:3695–9.
38. Schnittman SM, Lane HC, Roth J, et al. Characterization of GP120 binding to CD4 and an assay that measured ability of sera to inhibit this binding. J Immunol 1988; 141:4181–6.
39. Lasky LA, Nakamura GM, Smith DH, et al. Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor. Cell 1987; 50:975–85.
40. Ho DD, Kaplan JC, Rackauskas IE, Gurney ME. Second conserved domain of gp120 is important for HIV infectivity and antibody neutralization. Science 1988; 239:1021–3.
41. Dalgleish AG, Chanh TC, Kennedy RC, Kanda P, Clapham PR, Weiss RA. Neutralization of diverse HIV-1 strains by monoclonal antibodies raised against a gp41 synthetic peptide. Virology 1988; 165:209–15.
42. Rusche JR, Javaherian K, McDanal C, et al. Antibodies that inhibit fusion of human immunodeficiency virus–infected cells bind a 24-amino acid sequence of the viral envelope, gp120. Proc Natl Acad Sci U S A 1988; 85: 3198–202
43. Proc Natl Acad Sci U S A 1988; 85: 8697
44. Looney DJ, Fisher AG, Putney SD, et al. Type-restricted neutralization of molecular clones of human immunodeficiency virus. Science 1988; 241:357–9.
45. LaRosa GJ, Davide JP, Weinhoid KW, et al. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science 1990; 249:932–5.
46. Gnann JW Jr, Schimmbeck PL, Nelson JA, Truax BA, Olston MBA. Diagnosis of AIDS by using a 12-amino acid peptide representing an immunodominant epitope of the human immunodeficiency virus. J Infect Dis 1987; 156:261–7.
47. Chang TW, Kato I, McKinney S, et al. Detection of antibodies to human T-cell lymphotropic virus-III (HTLV-III) with an immunoassay employing a recombinant Escherichia coli-derived viral antigenic peptide. Biotechnology 1985; 3: 905
48. Nara PL, Fischinger PJ. Quantitative infectivity assay for HIV-1 and -2. Nature 1988; 332:469–70.
49. Stanberry LR, Bernstein DI, Burke RL, Pachl C, Myers MG. Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. J Infect Dis 1987; 155:914–20.
50. Rhoads JL, Birx DL, Wright DC, et al. Safety and immunogenicity of multiple conventional immunizations administered during early HIV infection. J Acquir Immune Defic Syndr (in press).
51. Birx DL, Redfield RR, Tencer K, Fowler AK, Burke DS, Tosato G. Induction of interleukin-6 during human immunodeficiency virus infection. Blood 1990; 76:2303–10.
52. Levy JA. Mysteries of HIV: challenges for therapy and prevention. Nature 1988; 333:519–22.
53. Michael NL, Morrow P, Mosca J, Vahey MT, Burke DS, Redfield RR. Induction of human immunodeficiency virus type 1 expression in chronically infected cells is associated primarily with a shift in RNA splicing patterns. J Virol 1991; 65:1291–303.